Inside today

Page 4
Comorbidity in ADHD

Page 6
Women in humanitarian action

Page 9
The fallout of forced displacement

Page 10
A return to the phenomenology of illness

Page 13
Danish lessons on risk and resilience

Page 14
Update on eating disorders

Page 19
Negative symptoms crossing boundaries

Page 20
PRISM “a paradigm shift”

Live at EPA

Mobile rapid response teams avoid hospitalisation

A mobile rapid crisis response team in France that operates 24 hours a day, seven days a week, has contributed to destigmatisation and helped to avoid psychiatrisation in acute care, delegates were told at a symposium on the organisation of acute psychiatric care yesterday morning.

“[ERIC] helps the user realise his recovery in his everydayness,” said Dr Zeltner. “It facilitates access to care for the [primary consultation] and patients in rupture, and reinforces as well as complements devices that require it in the territory such as in old age and adolescense. It also is an appropriate response to suicidal crisis if the family cooperates.”

The name ERIC was chosen because it is an acronym, Dr Zeltner told delegates, and that avoids patients facing stigma. “We wanted people to be able to come to see us,” she said.

Continued on page 2
Mobile rapid response teams avoid hospitalisation

Continued from page 1

“We wanted for them to sound familiar with our structure, to avoid stigma for patients and family. Patients say, ‘I’m going to chez Eric’ as they’d say ‘I’m going to the hairdresser.’”

French mental health care, Dr Zeltner explained, is divided into catchment areas or ‘secteurs’ of between 70,000 to 100,000 adult inhabitants. Each sector is served by one psychiatric team whose responsibilities include continuity of care and prevention.

Emergency psychiatry is provided in general hospitals, with a psychiatrist on site 24 hours a day to provide short crisis intervention of a maximum of three days, and orientation. Access to emergency psychiatric care is obtained by telephoning the fire brigade or the special urgent medical aid service SAMU-15.

Offering an alternative to hospitalisation, ERIC complements existing support and is organised around a crisis team of mental health experts providing a multi-sector approach, said Dr Zeltner.

The team includes psychiatrists, psychologists and 15 nurses who are available every day and around the clock. They visit the homes of service users and their families within a catchment area of 600,000 people. “It facilitates access to prevention, treatment and care for the most vulnerable segments of the population – those who don’t ask for themselves,” Dr Zeltner added.

“It is a big team and we are in touch with three different hospitals. It is a very integrated team and a multi-sector approach. It completes the usual response from psychiatric emergency.”

For more than 20 years, the programme has supported 1,071 patients, from infancy up to old age, with the majority (n=611) aged 26 to 60. Frequent mental health disorder has accounted for the majority (56%) of cases dealt with by ERIC, according to Dr Zeltner, followed by schizophrenia spectrum (21%), bipolar disorder (11%) and support to caregivers (7%). Psychiatrists, general practitioners, social workers, SAMU and schools are among those involved in the multi-disciplinary response, with the process of crisis intervention beginning with a phone call usually from families (33%) although general practitioners can also refer patients.

“A phone call is the way people get in touch with us,” said Dr Zeltner. “As soon as the call comes we are armed with a response. The paradox of the mobile team is that, to be able to give a response we have to be careful [how] we are getting in touch with them. Noone can come to see us – people have to phone us first.”

Dr Zeltner highlighted how teamwork is a vital part of ERIC, by which means staff can accurately assess cases. This is achieved by discussion and reflection with the team in order to reach a creative approach for each individual patient. The focus is on evaluation, exploration and then mobilisation.

The first interview, she explained, is followed by intensive ambulatory follow-up, lasting up to four weeks and including medical and/or therapeutic consultations, home visits and phone calls.

For patients who are non-compliant, the ERIC team will try its best to get them the support they need, according to Dr Zeltner. This could involve visiting their home and putting a letter under the door and ensuring staff come back later to speak to them.

Her presentation outlined published quantitative research evidencing that mobile crisis teams avoid 50 percent of hospitalisation, that they can lower rather than increase readmission. There is also evidence that they meet the satisfaction of users, family and professionals, as well as reducing family burden. However, other studies show there is a limit to quantitative studies and no fidelity scale.

According to findings presented by Dr Zeltner, nearly seven in ten (68%) people who come into contact with ERIC are then seen within 24 hours, and four in five (80%) within 72 hours. Concluding her presentation, Dr Zeltner said that ERIC has made a positive contribution to the severely mentally ill community.
a person with frequent service use and previous coercion. Hence, a one-year contract was established with recruited patients. This enabled them to admit themselves without objection for a maximum of five days, and also to discharge themselves.

Patients were recruited from Danish national patient registers. 422 patients were recruited to the patient-controlled admission group. Two sets of analyses were performed on the group of patients recruited. The first used patients as their own control, one year prior to index date. The second analysis was propensity score matched in which patients were matched with five control inpatients and upon which basis survival analysis was conducted.

The primary outcome was the use of any coercive measure. Secondary outcomes included hospitalisation pattern, medication used, and self-harm and death by suicide. Descriptive measures were also collected on client satisfaction, global assessment of functioning, and the frequency of conversion from patient-controlled admission to treatment as usual.

Result of the before-and-after index analysis in the patient-controlled admission group revealed a significant reduction in any coercive measures (225 vs. 139; p=0.0001) as well as mean number of bed-days (75.2 vs. 58.2; p=0.0003). No significant reduction between groups in medication use or self-harm behaviour. Interestingly, a similar reduction in any coercive measures was also found in the treatment as usual group (1296 vs. 808; p<0.0001).

Propensity score matching was based on covariates including gender and diagnosis, where exact matching was achieved, and others covariates where near but not exact matching was achieved. “There were some imbalances, which is a limitation to this study,” commented Dr Thomsen.

From this data cumulative risk curves were plotted on any coercive measures, where no significant reduction was identified with patient-controlled admission over the three-year follow-up period. In an analysis of specific coercions such as compulsory admission, restraint and forced treatment, no significant reduction was found either. Similarly, analysis of self harm behaviour revealed no reduction.

Turning to service use and redeemed prescriptions at one-year follow-up, Dr Thomsen commented: “We actually found that patients in the patient-controlled admission group had a higher use of services.”

“We actually found that patients in the patient-controlled admission group had a higher use of services.”

Christoffer Torgaard Thomsen

The strength of this study was that it was the first large-scale longitudinal study to investigate patient-controlled hospital admission. We had recruitment from five regions, and each coercion is registered by law in Denmark, which ensures high validity. The main limitations were that patients were not randomly allocated to either groups. Although an RCT study is superior with better control of confounding indication, we tried to do our best with the propensity score matching to take these confounds into account. Also, in the registers we don’t have any scale of severity of symptoms, which also may have been an issue in this study.”

References

A dangerous cocktail

Understanding comorbidity in ADHD

Today, suicidality is the theme of a clinical/therapeutic symposium where JJ Sandra Kooij (Associate professor of psychiatry, VU Medical Centre in Amsterdam), will address the comorbidity between attention-deficit hyperactivity disorder (ADHD) and mood disorders.

“Suicidality is obviously a part of depression and of bipolar disorder and when it is combined with ADHD this poses several additional risks,” she explained to EPA Congress News. “This combination can be dangerous due to low mood and impulsivity. The research shows that the suicide risk in ADHD is increased.”

Dr Kooij, who is also Head of the Dutch Expertise Centre Adult ADHD at PsyQ in the Hague, specialises in ADHD study beyond childhood, known to affect 3-5% of adults and older people. She will be discussing the prevalence of depression and other mood disorders because both are evident in adults with ADHD.

“Indeed, in clinical samples, 50% of those with ADHD suffer from lifetime depression. And bipolar disorder is also increased tenfold compared to the population level, especially type 2 bipolar disorder,” she explained.

The choices that must be made when treating patients with multiple disorders is a hot topic at present, and Dr Kooij will be discussing new research in this area: “If you have two or more disorders there is always an issue of the order of treatment. Which one do you treat first?”

Traditionally, for example, many psychiatrists were reluctant to treat bipolar patients with ADHD because of worries about inducing hypomania on commencement of ADHD treatment. But new research from Sweden has uncovered some very encouraging findings, according to Dr Kooij. “We now know that hypomania risk is reduced by treatment first with mood stabilisers. So it’s safe to give patients with bipolar disorder the stimulant under the protection of the mood stabiliser. That’s really good news.”

The use of mood stabilisers first has other ramifications, she added: “It means bipolar ADHD patients can be treated with the best treatments available to other people.”

Treating patients with two disorders is challenging, especially when one disorder is more severe than the other. “Usually the most severe disorder is the mood disorder. And when there is a severe disorder, it should be treated first.”

In ADHD and depression, people sometimes have resistance to antidepressants when we treat with antidepressants first.”

Dr Kooij

“In ADHD and depression, people sometimes have resistance to antidepressants when we treat with antidepressants first.”

Sandra Kooij

Dr Kooij speaks during ‘Attention-deficit hyperactivity disorder and suicide’, taking place in Thalie between 10:00 and 11:30 today.

References
Discovering ADHD in Adults

This meeting is initiated, organised and funded by Shire Medical Affairs.

Join us for a multimedia, expert-curated, educational experience on the recognition, diagnosis, and management of adult patients with ADHD.

Part of the European Psychiatric Association’s 28th European Congress of Psychiatry, 2018

Monday, March 5th
18:30–21:30 (join us anytime)
Mediterranée Room (Level 1)
Nice Acropolis Convention Centre, Nice, France

This programme is not intended or eligible for continuing medical education (CME) or continuing education (CE).

Approximately 3.4% (95% CI: 3.4-3.5) of adults worldwide may have ADHD.1

Many of them, however, may not be diagnosed.

Fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.2

1 adult in 30 may have ADHD.

10.9% of adults with ADHD* have received treatment in the past 12 months.3

*USA cohort

Please visit http://install.events/epasymposium to download the symposium App.
To register and access full symposium information please click on ‘Login with SSO’, in the ‘Domain’ enter: epasymposium and create your profile.

Faculty

Philip Asherson, MBBS, MRCPsych, PhD is Professor of Social Genetic and Developmental Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK, a Consultant Psychiatrist at the Macmillan Hospital; and a National Institute for Health Research Senior Investigator

Anthony L. Restaino, MD, MA is a Professor of Psychiatry and Pediatrics at the University of Pennsylvania Perelman School of Medicine, USA and is Education Committee Co-Chair of the American Professional Society of ADHD and Related Disorders (APSARD)

Martin A. Katzman, BSc, MD, FRCPG is Chair of the Anxiety Disorders Association of Canada; an Adjunct Professor at Adler Graduate Professional School and is Director of the START Clinic for Mood and Anxiety Disorders, Ontario, Canada

Susan J. Young, BSc (Hons), DClinPsy, PhD, CSSI, AFBSI is the Director of Psychology Services Limited and an Honorary Professor at both Reyjavik University, Iceland and Bucks New University, UK. She is President of the UK ADHD Partnership; Vice-President of the UK Adult ADHD Network; and is a Trustee of The ADHD Foundation, UK

Josep Antoni Ramos-Quiroga, MD, PhD is a Professor of Psychiatry at Universitat Autonoma de Barcelona, Spain and is Head of the Department of Psychiatry at Hospital Universitari Vall d’Hebron, Spain

References
2. Gladding V et al. Prim Care Companion CNS Disord 2015; 16:4; PCC.15m1950

© Shire 2018. All rights reserved. Shire and the Shire logo are registered trademarks of Shire Pharmaceuticals Holdings Ireland Limited or its affiliates.

VI MECOM-5710
Date of Preparation: January 2013
“Women must be involved on all levels of humanitarian action”

Michaela Amering

Today’s Presidential symposium characterises the issues of mental health in humanitarian emergencies. Michaela Amering (Medical University of Vienna, Austria), speaks specifically on the value of empowerment of women and girls in this setting and how this can be better facilitated, as well as the unique challenges they experience.

“Women are at elevated risk of many forms of gender-based violence and have their sexual and reproductive rights and health needs undermined in life-threatening ways,” Professor Amering told EPA Congress News.

The United Nations Population Fund estimates that 34 million women of reproductive age, 5 million of whom are pregnant, will need humanitarian assistance and protection in 2018. The need for better obstetric and newborn care is implied by the fact that 60% of preventable maternal mortality deaths take place in settings of conflict, displacement and natural disasters, according to a recent Care International report.

“There is also convincing evidence on the impact of different contraceptive measures and the need to integrate safe abortion and post-abortion care into emergency care,” noted Professor Amering, adding: “While the lack of bathroom equity and the so often deplorable menstrual hygiene situation are a terrible disadvantage for women under even the best of circumstances, in humanitarian crisis situations they constitute grave extra risks for women and girls.

“The heightened interest in investment in gender responsive humanitarian programming, however, does not only stem from awareness of women’s specific needs and wanting to stop failing them, but also from the experience that investment in women can impact the whole community and can make help more effective for all.”

In general, women and girls are used to keeping and expanding their roles and their resilience in the face of adversity, explained Professor Amering. However, the risk of men losing their accustomed roles or taking over traditionally female roles can create additional risks for women. Pre-existing disadvantages in rights and resources can lead to women and girls being the first to lose access to scarce resources like food and water. Girls’ education is endangered to an even greater extent than boys’, and the risk of child marriage can increases dramatically for girls. The specific needs and resources of adolescents in humanitarian crises, however, currently still feature as one of many data gaps.

The specific needs and resources of adolescents in humanitarian crises, however, currently still feature as one of many data gaps. “There is some knowledge on how programs can address underlying dynamics of power abuse and violence in affected communities, continued Professor Amering, adding that these necessary efforts have nevertheless been listed as remaining data gaps in recent comprehensive reviews. Such measures allow for earlier prevention and protection, as well as comprehensive clinical and psychosocial care for survivors to be characterised and implemented.

“Evidence-base, economic as well as human rights perspectives all do agree on the fact that women must be involved on all levels of humanitarian action such as prevention, response (including search and rescue), recovery and rehabilitation, community rebuilding and peace-building.”

However, not all consequences of specific strategies to harness the increased effectiveness that women’s participation in emergency aid brings are well understood. There is a risk, therefore, of unintended consequences, suggested Professor Amering, exemplified by historical and recently-reported backlashes against the gender equality movement.

Another factor in fostering positive gender relations in the humanitarian setting is female representation in leadership roles in institutions involved. “One main factor that should be a focus of change is the need for better female representation among aid workers on all levels, including local and international leadership,” commented Professor Amering.

“The current sexual misconduct and abuse crises in some humanitarian organisations might be an opportunity for decisive changes in this regard too.”

Professor Amering went on to discuss a parallel development to the evolving policies and practices in humanitarian crisis situations, concerning persons with disabilities. The UN-Convention on the Rights of Persons with Disabilities (UN-CRPD) was negotiated for the first time in history with the full participation of persons with a lived disability.
Pascal–Boyle award goes to Anita Riecher-Rössler

EPA honours Anita Riecher-Rössler, the first woman full professor of psychiatry in a German-speaking country, at this year’s Opening Ceremony. Professor Riecher-Rössler is well-known for starting the first specialised clinic for the early detection of psychosis in Switzerland, and has conducted important studies aimed at identifying early predictors of psychotic disorders.

During an interview with EPA Congress News, she began by describing how her early career developed: “I think I have at least tried to promote the field in the direction of early detection, intervention and prevention in the area of psychoses,” she said. “Interest started when I was the deputy chair of a research project on gender differences in psychoses, which later was called ‘ABC Study’ (age, beginning, and course of schizophrenia), led by Heinz Häfner in Mannheim, Germany.”

The group uncovered, first, that psychotic disorders start with unspecific prodromal and sub-threshold psychotic symptoms many years before the patients developed their first frank psychotic episode. “Even then, it took long time until they sought help,” noted Professor Riecher-Rössler.

The second finding was that women developed disorders on average several years later than men and had a second peak of onset after the age of 40. “Both findings made me very curious,” said Professor Riecher-Rössler.

“In the beginning, my main interest was in explaining the gender difference in age of onset, and I performed several studies on that – amongst others, on the potential influence of the female sex hormone oestrogen as one possible explanation.”

“I think I have at least tried to promote the field in the direction of early detection, intervention and prevention in the area of psychoses.”

Anita Riecher-Rössler

References
ments in mind: “Women have long been discriminated against, including in the fields of mental health care and psychiatry,” she explained. “Through this prize, the EPA aims to publicly acknowledge and increase awareness of the outstanding achievements by women in working to improve mental health care in Europe.

“Anita Riecher-Rössler was chosen for her academic, clinical, research and leadership skills. She is constantly committed to improving and expanding knowledge on mental health. She has contributed to advancing research and care for emerging psychoses and has conducted important studies aimed at identifying early predictors of severe psychotic disorder.”

“She has also provided important research contributions on specific aspects of mental disorders in women, particularly on psychoneuroendocrine and psychosocial risk factors for mental disorders, as well as on gender-sensitive (psycho) therapies.”

Professor Riecher-Rössler has been a leading figure in women’s mental health associations too, added Professor Galderisi. As well as being Editor-in-chief of the Archives of Women’s Mental Health, she has published about 330 original articles (225 peer-reviewed), edited 28 books (15 as series editor) and has authored 98 book chapters.

The Pascal – Boyle prize was inspired by two trailblazers who lived and worked early last century. Dr Constance Pascal was a Romanian psychiatrist who became the first woman to qualify as a psychiatrist in France in 1908. By 1925, she had risen to become the first female director of a French psychiatric hospital, as chief physician at the Moiselles.

Dr Helen Boyle, an Irish-British psychiatrist, started work in 1894 in England and went on to become the first female President of the Royal Medico-Psychological Association (later to become the Royal College of Psychiatrists). “Both contributed significantly to the scientific literature in addition to their pioneering clinical work, and served as role models for generations of future female psychiatrists,” noted Professor Galderisi.

A century on and modern-day psychiatrists such as Professor Riecher-Rössler find themselves occupying similar positions: “I was very pleased and grateful to all the women and men who supported me during these years,” she said. “Especially rewarding were the mails I got from young female colleagues, telling me that I was a role model for them. It reminded me that I also had many wonderful role models here in the EPA – and how important that was.”

Asked how she perceives progress in gender equality, she replied: “Yes, I have seen women in psychiatry progress. Some years ago the EPA appointed the first female president, Danuta Wassermann, and right now we have the second, Silvana Galderisi. Similarly, the World Psychiatric Association now has its second female president with Helen Herrman – both associations have done so after a long tradition of only male presidents.”

Despite that, there remains room for improvement: “Why is it that the majority of psychiatrists are female in most countries but they are still not equally represented in influential positions?” asked Professor Riecher-Rössler. “I have therefore tried to advance the careers of young women in psychiatry – for example by mentoring and workshops – because I think that psychiatry as a whole could gain from having leading and influential figures of both genders.”

In her concluding remarks, Professor Riecher-Rössler described her priorities going forward: advancing the shift from traditional treatment-oriented psychiatry towards the inclusion of early detection, intervention and prevention; advancing the field of gender-sensitive psychiatry and psychotherapy – for both genders; and advancing young women’s careers to promote them into more leadership positions.

“That is the best approach for our field and our patients,” she said. “I am very grateful and optimistic. Psychiatry as a field is developing enormously positively and there are so many really brilliant and dedicated people – women and men – who will advance the field even further.”
Forced displacement “a human-made psychosocial earthquake”

EPA Board member Levent Küey, Associate Professor of Psychiatry at Istanbul Bilgi University (Turkey), will give the Congress an update this morning on the work of the EPA Task Force on Needs of Refugees and Asylum Seeker Patients in Europe, which he chairs.

In 2015 the EPA reacted to growing rates of forced displacement with a position statement¹ and set up the EPA Task Force on Needs of Refugee and Asylum Seeker Patients in Europe, dedicated to work on the mental health consequences of forced displacement, and the psychiatric care of refugees.

Speaking ahead of his presentation, Professor Küey told EPA Congress News: “By the end of 2015, one in every 122 humans was someone who had been forced to flee his home. In 2016, this number rose to 65.3 million.”

He explained that if this were the population of a country, it would be the 22nd most populated country in the world and 4th of such in Europe. During 2016 nearly 34,000 people were forcibly displaced every day.

The psycho-social context of mental health consequences

The mental health consequences of the forced displacement of people are shaped by psychosocial, cognitive and emotional context, underlined Professor Küey.

He said: “A forcibly-displaced person is experiencing a human-made psychosocial earthquake. Nobody wants to flee forcibly, and it is not on their free will, i.e., not a choice. Furthermore, it is not pre-planned; usually the decision and action to flee are made in a short time, following one after the other. "A refugee is under threat in all areas of attachment, mastery, and survival. Almost all attachments are left behind, degree of mastery over one’s own life is decreased; the nutrition of the self and the self-image are devastated. And basic needs for survival are maintained mostly in the mercy of others. "A refugee is a person who has lost the past for an unknown future. Experiences of loss and danger are imprinted in their selves, increasing their vulnerability for depressive and anxiety disorders.”

Mental health fall-out of displacement

There is increasing evidence that a large proportion of refugees and asylum seekers residing in Europe suffer from the consequences of traumatic events, and exhibit mental health problems such as post-traumatic stress disorder (PTSD), said Professor Küey.

In general, he said, mental health consequences of forced displacement include PTSD, depressive disorders, anxiety disorders, psychosis, and dissociative disorders. Refugees resettled in western countries could be about ten times more likely to have PTSD than age-matched general populations.

“Once more, psychiatry and mental health workers are facing the mental health consequences of persecution, general violence, wars, and human rights violations caused by the current prevailing economy-politics and socio-politics,” he said.

A serious challenge is consolidating the psychiatric/medical help on one hand and avoiding the medicalisation of social phenomena (armed conflicts, persecution and wars) on the other.

How the EPA is tackling the crisis

The EPA’s Task Force has been actively working on the related issues of the mental health consequences of forced displacement and the needs of refugee and asylum seeker patients in Europe, aiming to finalise its work in 2019, said Professor Küey.

Summarising the Task Force’s achievements so far, he highlighted the organisation of a series of scientific sessions including symposia, workshops and EPA CME courses targeting psychiatrists and mental health workers, held in Madrid in 2016, and Florence and Berlin in 2017. These activities continue at the 2018 Congress.

Professor Küey said the final version of the Task Force Position Paper and report is being updated and edited and will be submitted to European Psychiatry. A critical review and a list of the current practice of e-mental health initiatives in Europe will also be published.

The EPA Task Force has also collaborated with the EU Health Policy Platform Thematic Network on Migration and Health, contributing on issues of stigmatisation, discrimination and mental health aspects. The group has prepared a general framework document and a call to action.

Other activities planned include a systematic review article on the subject of forcibly displaced people and mental health, to be prepared by the Task Force members.

Professor Küey noted that proposals for scientific sessions targeting physicians and non-mental health workers will also be prepared, and possibilities of collaboration with the World Medical Association and similar organisations will be explored. In collaboration with the EPA and national psychiatry associations (NPA), the possibility of undertaking a research and/or assigning a key person in each NPA will be investigated. Via this contact, all relevant activities and initiatives in each NPA country will be documented.

A critical review is also planned, as well as a list of the current practice of any health promotion activities, psycho-educational interventions, psychotherapies (including specific therapies), resilience and/or resource-oriented interventions. This information will be gathered within a section of the EPA website on forcibly-displaced people and mental health.

The workshop, ‘How do EPA, WPA and WHO Respond to the Mental Health Consequences of Forced Displacement?’, takes place in Erato from 8:00 to 9:30 this morning.

References


“By the end of 2015, one in every 122 humans was someone who had been forced to flee his home.”

Levent Küey
Person-centred psychiatry comes centre stage this morning in a workshop focussed on the importance of phenomenological psychopathology. Not only is it a rigorous understanding of clinical phenotypes clinically relevant, but it is crucial to the development of rigorous research — such is the thinking of Giovanni Stanghellini ("D'Annunzio" University, Chieti, Italy), who speaks during the session on person-centred dialectical models in schizophrenia, and who chairs the EPA's Philosophy and Psychiatry section.

"This is actually the basis for understanding what it is like to be in the patient's shoes," he told EPA Congress News. "What is the universe in which that specific patient lives? We think this is the basis for good clinic and good research."

The experiential dimension of mental disorder is downplayed in contemporary approaches, he added. In contrast behaviours and cognitive traits, while part of the experiential domain, are not a complete representation of a patient's lifeworld. Once the lifeworld is rigorously defined, the patient can then take a position in front of her experiences: "If you have a patient who hears voices, standard assessment says that this patient is hallucinating," said Prof. Stanghellini. "But one patient may be totally overwhelmed by his voices, while another may react and try to contrast them, and another patient may see them from 'without'."

"This is of the greatest importance to understand the patients themselves. Person-centred psychopathology means, first, emphasis on subjective experience and, second, an emphasis on the way the person deals with, makes sense of, or copes with these subjective experiences."

Why is this relevant? "To establish a valid and reliable diagnosis, symptoms of experience are by far more reliable than behaviours. Behaviours are very unspecified. Consider the following behaviour: a person who does not eat. Can we say that she is anorexic? No we can't. What counts is the mental state that subsumes her behaviour. The person may not eat because she thinks that food is poisoned (sitophobia), or because she is convinced that this sort of food is not healthy for her (orthorexia), or she may be a follower of a sort of 'religion' attributing a negative value to food and to fat (as it is often the case with people with so-called eating disorders' as shown in Ana blogs in the internet).

You have to understand what the experience behind it is and the meaning that the patient attributes to the experience."

Prof. Stanghellini went on to describe how person-centred dialectical principles can be applied in the therapeutic setting, relating the experiences of a patient to a ballad up manuscript, upon which her lifeworld is written. In order to come to terms with it, the task of the patient (with the help of the clinician) is to first unravel this page. Second, the patient is invited to take a position in front of it. Third, patient and clinician cooperate to trace the relation of these present experiences to the patient's personal history. While facilitated by the clinician, this process has the effect of instilling a sense of agency in the patient, which goes hand-in-hand with recovery.1 2

That phenomenology and biology remain so apparently at odds with one another underscores the need for structures that bridge them. Prof. Stanghellini explores this in his research, defining the abnormal bodily experiences in persons with schizophrenia in terms of abnormal spatiotemporal experience, which can then be related to brain structure and function.3

"How can I find biological correlates for something that is not properly phenomenally defined?" Without doing this, I wonder what neurobiological research is looking for. It is looking for correlates of something that is only blurrily defined."

Some of his recent work looks at defining 'pheno-phenotypes' — characterisations of different types of lifeworlds — and how these can be directly correlated to biological structure and function.4 Research into pheno-phenotypical characterisation is underway in a number of different disorders including schizophrenia, major depression, obsessions, eating disorders, borderline personality disorder, addictions, said Prof. Stanghellini, adding that these are available in the most recent edition of the Oxford Handbook of Phenomenological Psychological research that will shortly be available online.

"Of course we need to integrate the experiential data and facts with the biological data and facts," he continued. "The real problem nowadays is that most of research and fundings of research are on one leg: biological research. The need to reiterate that there is an experiential dimension that is clinically relevant, and not just ethically relevant, derives from the fact that the majority of funding is in the direction of biological psychiatry."

"The education of young psychiatrists is basically biologically oriented. But psychiatrists do not sit in front of a brain - we sit in front of a person.5"

References
Abandoning preconception
The sensation of the melancholic

Otto Doerr-Zegers (Professor of Psychiatry at the Universities of Chile and Diego Portales; Director of the Center of Studies on Phenomenology and Psychiatry, Diego Portales University, Chile) continues the theme of person-centred psychiatry with an exploration of the phenomenology of depression. The underlying phenomena of psychiatric illnesses – experienced by the patient and intuited by the physician – can not be directly observed, he said, but should remain of central importance in psychiatric research and treatment.

Symptoms as emergence of phenomena
In a 1958 paper, Henricus Rümke observed that all the primary symptoms of schizophrenia illnesses are unspecific, appearing in other illnesses and indeed in healthy individuals too – despite the ability of the psychiatrist to make concrete diagnoses on the basis of extensive patient evaluation. The fact that diagnosis is possible at all, suggested Professor Doerr-Zegers, calls for a clarification of the concepts by which elements of psychopathology are distinguished: “The merit of Rümke is having pointed to the essence of schizophrenia,” he said, “In spite of the somehow necessary tautological character of the diagnostic process in psychiatry, given the fact that in these diseases no substrate has been found in which the diagnosis can be based.”

There is, said Professor Doerr-Zegers, an intuitive sensation (the ‘prechex feeling’) the physician has when facing patients with, for example, schizophrenia: “[In capturing] this specific atmospheric emanation, we not only arrive at a more precise diagnosis of this illness, but this intuition of the essence can lead to future research in order to discover the neurobiological fundamentals of the disease.”

He pointed out that the relationship of contiguity between isolated symptoms was identified as a methodological limitation in the current diagnostic manuals of major depressive disorders. What is important is the relation between these symptoms, and this can be uncovered by examination of the phenomenology of the illness.

Moreover, he added, the phenomenological experience brings forth the unifying, invariant characteristics of patients with, say, schizophrenia or depression. A key distinction must therefore be made between symptom and phenomenon, with a symptom definable as a manifestation of the underlying phenomena fundamental to the illness. This distinction is important, he explained, because a confusion of symptoms with phenomena can lead to conceptual errors in all areas of psychiatric investigation and practice.

Lessons from the phenomenology of schizophrenia
Illustrating the importance of a conceptualisation of psychopathology that reflects a patient’s experience, Professor Doerr-Zegers used the example of auditory hallucinations that a person with schizophrenia experiences: “For a long time it was thought that if someone listened to objectively non-existent voices, he must have a disturbance of his hearing system. In fact, many investigations were performed in search of that acoustic disturbance and all were fruitless.”

Conceptual errors are often evidenced by confused medical vocabulary. That a patient “hears voices”, explained Professor Doerr-Zegers, is imprecise: a characteristic of schizophrenic hallucination is the simultaneous experience of being invaded, overwhelmed. As such, the person with schizophrenia is not an active agent (as people may be with other hallucinogenic experiences), but experiences “being spoken to” (as described by Jürg Zutt in 1963). This distinction unveils the feelings of perplexity and helplessness that a person with schizophrenia experiences. Such a reconceptualisation is important in marking out those characteristics specific to the illness.

Characterising the melancholic experience
Professor Doerr-Zegers applied this same idea to his patients with depression at the Psychiatric Clinic of the University of Chile. These empirical-phenomenological investigations yielded three principle elements of the depression experience – the ‘melancholic sensation’ – that are consistent across its clinical manifestations.

First, he explained, the patient’s experience of their own body changes, manifesting in symptoms such as compromised mood, anxiety, lack of energy, pains and feelings of cold. Second, the relation of their body with the world is altered, resulting in symptoms such as difficulty in concentrating, decision-making and acting. Third, a change in temporality is expressed as aberrations in vital rhythms in areas such as eating, sleeping, and sexuality.

“These constitute the fundamental phenomena of depression and must always be present for making the diagnosis. The combination of signs and symptom can be different in each patient, but the three phenomena have to be there, because they belong to the essence of depressivity.”

These findings emerged from investigations beginning in 1971 at Professor Doerr-Zegers’ clinic. 50 patients, recruited over a five-year period, were systematically characterised in terms of symptoms, observations from clinicians and family members, and patients’ subjective experiences as recounted by them. Thereupon, the investigators sifted out personal, familiar and socio-cultural differences to reach a set of phenomena that were consistent.

“At the end of each morning we had a team meeting, where we studied together an average of five of the more interesting new patients,” said Professor Doerr-Zegers in describing how these studies came about: “Very soon it became evident to us that one of the more urgent tasks should be the conceptual clarification, the definition of the syndrome and the establishment of clear differential criteria in the framework of the diversity of depressive cases offered by clinical practice.”

“The wilt of the lived body is the beginning of this process of becoming a thing. And so, all the particular symptoms order themselves around the disturbance of embodiment. This ‘phenomenon’ (and not ‘symptom’) must always be present for diagnosing a depression. And in the measure...”
Abandoning preconception

Continued from page 11

that it corresponds to the essence of this disease, it can lead researchers to future developments [reaching down to] the molecular level.”

Contrasting the phenomenological diagnosis with the atomised approach

Professor Doerr-Zegers distinguished the phenomenological diagnosis from the symptom-based diagnosis, saying that the former takes the phenomenon (e.g. the diagnosis of depression) as a holistic structure and starting point of investigation of the patient. “It does not develop from elementary entities (symptoms) towards a nosological configuration or syndrome. Rather, it starts from a complex structure (phenomenon), from which the single symptoms may be unfolded.

“In this way, the symptoms can only be described through the analysis or the composition of the holistic phenomenon, as parts of the same whole. Thus, among the advantages of the phenomenological diagnosis is that it takes into account, on the one hand, both the inner relation between the phenomenon and the symptoms, and the immanent interconnections between the symptoms, on the other.

“These are not ‘independent parts’ or pieces, which are isolated and contiguous, as in the symptomatological diagnosis. They are rather ‘dependent parts’ or ‘moments’ structurally interconnected within a whole phenomenon. The phenomenon is, by definition, experienced/ co-constituted by the patient and the clinician. It corresponds to the patient’s self-experience and includes the way the patient’s experience is lived by the clinician.”

That psychiatrists routinely draw on such intuitively-acquired knowledge speaks to its important implications for research, said Professor Doerr-Zegers. That is, knowledge from direct sensory perception – that forms the basis of the scientific method – is insufficient in adequately describing what it is like to experience something.

The methods of the natural sciences can be applied to physical

References

Danish high risk and resilience studies
Targeting the early years

Merete Nordentoft (Research Unit at Mental Health Center Copenhagen; iPSYCH - The Lundbeck Foundation Initiative for Integrative Psychiatric Research; University of Copenhagen, Denmark) presents knowledge in prevention, care and research gleaned so far from the Danish high risk and resilience study (VIA 7)1 during her plenary lecture this morning at EPA 2018.

This representative nationwide cohort study is a close collaboration with the Research Department P at Aarhus University Hospital Risskov & Aarhus University, and the Child and Adolescent Mental Centre Copenhagen. It was initiated in 2013, since then establishing a cohort of 522 7-year-old children and their parents, recruited on the basis of one parent, both parents, or neither having been diagnosed with schizophrenia spectrum psychosis or bipolar disorder. The study’s aim was to analyse the influence of genetic risk and environmental factors.1

Professor Nordentoft has played a leading role in the development and implementation of early intervention services in Denmark and initiated the VIA 7 study, which is currently at the stage of reassessing its cohort of children at the age of 11, along with their parents. Professor Nordentoft is also involved in the Integrative Psychiatric Research (iPSYCH) consortium, which has generated genomic data that will be linked with environmental aetiologies for a number of severe mental disorders2.

It is known that individuals whose parents have mental disorders are themselves at a higher risk of becoming mentally ill, Professor Nordentoft told EPA Congress News – not only of developing the same disorder as their parent or parents, but others too: “We have looked into register based information about these children, and we can see that they have approximately twice as high a risk of getting child psychiatric disorders compared to children whose parents do not have any mental illness. The most common mental disorders in childhood among these at high risk are anxiety and ADHD. And if both parents have a mental illness, the risk goes up again.”3

Professor Nordentoft has played a leading role in the development and implementation of early intervention services in Denmark and initiated the VIA 7 study, which is currently at the stage of reassessing its cohort of children at the age of 11, along with their parents. Professor Nordentoft is also involved in the Integrative Psychiatric Research (iPSYCH) consortium, which has generated genomic data that will be linked with environmental aetiologies for a number of severe mental disorders.

It is known that individuals whose parents have mental disorders are themselves at a higher risk of becoming mentally ill, Professor Nordentoft told EPA Congress News – not only of developing the same disorder as their parent or parents, but others too: “We have looked into register based information about these children, and we can see that they have approximately twice as high a risk of getting child psychiatric disorders compared to children whose parents do not have any mental illness. The most common mental disorders in childhood among these at high risk is anxiety and ADHD. And if both parents have a mental illness, the risk goes up again.”

In such children, unspecific symptoms such as neurodevelopmental delays, cognitive deficits and social adversities, are more common. Professor Nordentoft stressed that clinicians should be aware of and address the issues of children of people in psychiatric treatment: “It could be that they already have developed a mental disorder, but it could also be that the children are vulnerable more generally.

“We know that they have cognitive challenges – not every child, but on average they have a poorer level of cognitive functioning. We also know a lot about their conditions: many of them live in less stimulating home environments.

“It is needed for all the psychiatric services and the services in municipalities to focus on these children, who might need some help and whose parents might need help too. Also, the children would like to know and understand, at least at a certain age, what kind of problems their parents have and how to deal with them.”

These are very immediate clinical measures. In the longer term, it will be crucial to understand how these at-risk children will develop throughout their teen years – during which period illnesses such as schizophrenia and bipolar disorder can precipitate.

Indeed, the characterisation of early markers of psychiatric disorder is one objective of Professor Nordentoft’s work. Last year, she and colleagues published on the presence of abnormalities in fine motor development among these at high risk.

“Continued on page 14”

References
Danish high risk and resilience studies

Professor Nordentoft delivers ‘High Risk and Resilience Studies: Lessons for Prevention, Care and Research’ today in Athena between 11:45 and 12:30.

State of the art: Advances in (adolescent) eating disorder

Eating disorders

Evidence and new approaches

Treatment for ‘food addiction’, support for carers and early diagnosis are some new approaches to treating adolescent eating disorders.

Janet Treasure, Professor of Psychiatry and Director of the Eating Disorder Unit at the Institute of Psychiatry, King’s College London, and the South London Maudsley Hospital, told EPA Congress News about newer strategies for dealing with specific eating disorders and stressed the importance of early intervention and family involvement in treatments.

Early intervention and family/carer involvement is key to treating anorexia nervosa, but treatment for binge eating disorder and bulimia nervosa may need targeted treatments for food addiction similar to substance misuse strategies, explained Professor Treasure.

Summarising evidence of the most effective options currently in use, and newer approaches, she said: “Progress is slow, treatment takes time, and there has been little investment in research.”

Recovery from anorexia nervosa

Professor Treasure acknowledged that engagement of the individual in treatment can be difficult, and that patients prefer outpatient psychological therapy which has a focus on socio-emotional and cognitive management over drug treatments and nutritional advice.

“A form of early intervention in which the family is involved is to support eating disorder patients with inpatient care for severe anorexia nervosa with high medical risk improved weight and give carers respite,” she said, concluding: “We scan them when they are 11 years old and we will follow them prospectively. That will give us more insight about what happens in the brain when children get ill.”

Bulimia nervosa and binge eating disorder treatment

Increasing number of people in the UK were diagnosed with bulimia nervosa (BN) in the 1980s and binge eating disorder (BED) in the new millennium. This increase in eating disorders parallels the worldwide increase in the prevalence of obesity. “Fatness is stigmatised and ‘fat talk’ is associated with body dissatisfaction and abnormal eating prac-
tices, while thinness and muscularity are valued as the ideal body form,” said Professor Treasure.

Professor Treasure says current treatments for BN and BED are only moderately effective with 30 to 50% of individuals achieving complete abstinence at the end of treatment, and a 68% remission rate at nine years follow-up.

“This suggests the transdiagnostic model that underpins cognitive behavioural therapy may require modification to accommodate the diverse eating patterns and weight across the eating disorder spectrum,” says Professor Treasure.

New research10 recently published by Professor Treasure proposes an updated model of BN and BED, stemming from the food addiction hypothesis. She said animal studies have demonstrated that manipulations of the food environment can produce ‘binge eating’. Putative risk factors including a period of undernutrition followed by the intermittent addition of palatable food (high sugar and fat combinations), and stress (particularly social stress).

“Food addiction implies neuroadaptation – learning which leads to craving and tolerance,” explained Professor Treasure. “It follows from this model that certain foods may have an addictive potential because of a similar change in the pharmacokinetics of glucose (rapid glucose flux) and possibly fat metabolism.

“For example, foods with a high glycaemic load have the potential to cause greater fluxes in blood glucose. A survey examining the addictive potential of different foods found that technologically processed foods with added refined carbohydrate and fat and / or with a higher glycaemic load were most implicated.”

Professor Treasure said that recurrent binge eating of foods high in fat and sugar has been associated with desensitisation of opioid and dopamine receptors. This pattern mimics the neural underpinning of tolerance and dependence observed in substance use disorders.

“Greater recognition of the similarities in neural processes observed in binge-type eating disorders and substance addiction may facilitate the development of new treatments that target critical maintenance factors,” she said.

Professor Treasure recommended several possible treatment targets for food addiction including: recommending patients avoid and abstain from technologically-modified foods that trigger overeating, or to manage them in a way that reduced harm rather than encouraging an absolute no-dieting approach. Other treatments she mentioned included strategies to counteract impulsivity and habitual pattern of responding, using computerised approaches and virtual reality. New drugs which target the sensitisation to food cues, while preventing receptor tolerance triggered by binge eating, could also be used. Other possible treatment models include developing positive anxiety management and coping mechanisms to deal with high levels of stress and reward seeking behaviour.

More research is needed though, and Professor Treasure identified several areas to focus on including: discovering the most relevant ‘food approach traits’ determining susceptibility to BN or BED; the most relevant food avoidance traits; identifying behavioural interventions that would be most effective for breaking the automatic stimulus response association and finding out which drug treatments would be effective in curbing recurrent binge eating behaviour.

Professor Treasures delivers her State of the art lecture today in Hermes from 15:00 until 15:45.

References
New era of earlier diagnosis and treatment ahead for patients with bipolar disorder

Eduard Vieta, a leading authority on bipolar disorder from the University of Barcelon, Spain, told the Congress yesterday that psychiatry is entering a new era in the treatment of bipolar disorder with earlier diagnosis, precision psychiatry and new technology, as well as patients and families, set to play increasingly important roles.

Earlier intervention in bipolar disorder may help to change outcomes of the illness and avert potentially irreversible harm to patients. Earlier phases may be more responsive to treatment and need less aggressive therapy, Professor Vieta told EPA Congress News. “Early intervention in bipolar disorder is gaining momentum. Current evidence from longitudinal studies indicates parental early onset bipolar disorder is the most consistent risk factor for bipolar disorder.

“There are also identifiable risk factors that influence the course of bipolar disorder, some of them potentially modifiable. Valid biomarkers or diagnostic tools to help clinicians identify individuals at high risk of conversion are still lacking, although there are some promising early results.”

Professor Vieta said current research supports the idea of an at-risk state in bipolar disorder, laying the foundations for bringing early intervention to fruition. “We cannot deny however that further efforts are required to advance on the difficult road of primary prevention.

“Given that psychiatric and commonly comorbid medical disorders share common risk determinants and operative biological pathways, a shared framework for disease prevention and control is warranted.”

As such, a cross-disciplinary, multi-target approach is essential for wide-scale implementation in real-world settings, with an unquestionable need for new prospective studies with a larger sample size and standardised recruitment criteria and assessment tools.

Professor Vieta explained that such studies should assess the validity of the proposed predictive factors, to better determine which individuals are at highest risk for conversion and therefore more likely to benefit from early interventions. Further studies on early psychological and pharmacological interventions, either alone or in combination, are equally warranted.

“In conclusion, considering that the onset of bipolar disorder usually occurs during adolescence – a period of personal, social, and professional development that is often truncated by the illness – introducing early interventions in psychiatry is imperative.”

He went on to say that one of the critical changes of the paradigm is the emerging involvement of families in the diagnostic and therapeutic processes. “Time is over for paternalistic medicine. Patients want to know and want to decide. What they want is ‘my life back’, with more focus on social functioning than on symptoms.”

He then highlighted research by the ENIGMA consortium’s bipolar branch, which produced mapping of the bipolar brain showing the structural changes of patients with bipolar disorder compared to controls, showing grey matter loss in some key regions.

He also suggested that pharmacogenetics will become increasingly important. He cited the ConLiGen consortium that recently published a large genome-wide association study identifying a single locus of four linked single nucleotide polymorphisms on chromosome 21 met genome-wide significance criteria for association with lithium response.

Technology will also play an increasing role in diagnosing and treating bipolar disorder, noted Professor Vieta. Examples include mobile-based interventions, self-monitoring and psychoeducation via smart phone apps, deep brain stimulation, and devices to track treatment intake and adherence.

Psychiatry is moving towards personalised medicine, said Professor Vieta: “We are entering a new era in the practice of medicine in general, and in psychiatry in particular – especially in the case of bipolar disorders. We are not ready for true ‘precision psychiatry’ but clinical stratification is possible and useful. Biomarkers and pharmacogenetic tests are coming up and progressively inexpensive.

“An example is the increasing role of biomarkers and, for example, pharmacogenetic tests. In a few years I anticipate that these items will become increasingly important to give support to clinical diagnosis and treatment.”

“Psychiatry will become more technical, but the sensible empathic and expert clinician will always be necessary. The new developments in bipolar disorder will require that clinicians are totally up-to-date and ready to embrace innovation.”

References

“Time is over for paternalistic medicine. Patients want to know and want to decide.”
Eduard Vieta
RTMS for depression in Europe - It's time for approval from health authorities

Uranie Monday 15:00

rTMS in treatment-resistant depression: overdue for reimbursement in France

R

epetitive transcranial magnetic stimulation (rTMS) is of growing importance in the treatment of diverse psychiatric diseases\(^1\). For patients with treatment-resistant depression, rTMS has been approved in the US. In Europe, rTMS is increasingly used in some but not all countries, with several devices receiving CE marking\(^2\). Yet its use is not supported by routine reimbursement by healthcare systems in countries including France, despite its use both in psychiatric research and routine clinical care in the public and private sectors\(^3\).

In such a situation, said Anne Sauvaget to EPA Congress News, completing the transition from bench to bedside requires a collaborative effort between clinicians and health economists. “The idea of the symposium was to expose the economic and political issues of rTMS in Europe – and [specifically] for me in France, because I can’t speak for other countries.”

rTMS is not presently officially recognised by the French health authorities, she explained, which has created a contradiction between guidelines\(^4\) and what clinicians are able to deliver to their patients. Moreover, investment into rTMS systems will be worthwhile for hospitals only once it gains official status.

“I am part of the French Association of Biological Psychiatry and Neuropsychopharmacology (APFBN; http://www.aphbn.org), working with the section of this society involved in non-invasive brain stimulation. It is very important that [we provide] scientific and economic [data] for the ministry of health, to help rTMS be recognised. That is why, with some colleagues from my hospital, we evaluated the cost for a hospital of a treatment with rTMS for depression\(^5\). For us, this economic work was the first step in providing data to authorities that the treatment has an average cost of €2,000. For France, this is not a very expensive treatment compared to, for example, cancer or hepatitis treatment. And according to scientific literature, rTMS is an effective treatment for depressed patients. So it is very important that this treatment is reimbursed to avoid future treatment resistance, recurrence and also suicide for patients suffering from mood disorders.”

The methodology of this economic analysis was developed will all aspects of a rTMS session in mind. Validated by a multidisciplinary task force (of clinicians, public health doctors, pharmacists, administrative officials and a health economist), the analysis included in its remit cost of equipment, staff, and operational overhead costs. In this way, an effective treatment duration of 15 sessions was found to cost €1,932.94 (€503.55 for equipment, €1,082.75 for staff, and €346.65 for overhead expenses).\(^5\)

“We tried to build a methodology was as clear as possible,” said Dr Sauvaget, adding that this study is more comprehensive than the few that appear in the literature. Notably, most economic analyses compare TMS to electroconvulsive therapy (ECT), with basic cost analysis in TMS lacking.

Asked how she would like these data to be taken forward, Dr Sauvaget said: “It would be very interesting if, for example, a private clinic could conduct the same methodology, or another university hospital, just to compare if we have done it well. But as far as I know, no other people have conducted a similar study in France.”

She concluded with reference to the title of her presentation during this session, “A challenge for clinicians”, an acknowledgement of the difficulties of getting involved in health economics in the absence of formal training. “If we want to support our patients with energy, we clinicians have to be interested in economic health issues, and work with health economists to conduct strong scientific work to be taken seriously by administrative officials.”

The Symposium, ‘RTMS for Depression in Europe - It’s Time for Approval from Health Authorities’ takes place this afternoon in Uranie between 15:00 and 16:30.

References

“If we want to support our patients with energy, we clinicians have to be interested in economic health issues, and work with health economists.”

Anne Sauvaget
“It is important to personalise opioid treatment based on the risk profile of patients to develop opioid use disorders.”

Arnt Schellekens

Intimately connected Pain, psychiatry and addiction

The focus is on addiction in chronic pain, during a session that sees discussion of pharmaceutical pain management, prudent prescription amid fears of opioid crisis, and the associations between pain and alcohol use.

Arnt Schellekens, psychiatrist at the Medical Psychiatric Inpatient Unit of Radboud University Medical Centre (the Netherlands) and Scientific Director of the Nijmegen Institute for Scientist Practitioners in Addiction, co-organised the symposium.

“Attending this session will provide insight in the current trends in opioid prescriptions in Europe and how to prevent and treat iatrogenic opioid use disorders, without throwing away the child with the bath water,” he said during an interview with EPA Congress News.

“We will focus on the intimate connection between pain and psychiatry, and addiction in particular. One important question is whether the epidemiology of opioid prescriptions in Europe will follow the dramatic opioid epidemic in the US and Canada.”

Such discussions are highly topical – steps on prevention of such a European epidemic must be taken: “We also see the number of opioid prescriptions rising in Europe. However, opioids are excellent analgesics and a rise in prescriptions is not necessarily problematic,” he said.

“In order to prevent us following the US scenario, this is the moment to take action and to be keen on prevention and treatment.”

Delegates will also learn about the assessment of risk of development of opioid use disorders in patients with pain, which may be a useful preventative measure. The session will also address which treatments options are available once opioid use disorders have developed, noted Dr Schellekens, as well as the analgesic properties of alcohol.

Addiction is a specialty of Dr Schellekens’s department, which also has a strong research focus. Indeed, Dr Schellekens recalled a case that prompted much of the work that’s going on at present: “A couple of years ago we were confronted with the first patient with severe iatrogenic opioid use disorder, combined with chronic pain,” he said.

The patient had been admitted to various departments within the hospital, had undergone repeated operations and experienced rather dramatic complications, including a cardiac thrombus, he explained.

“She was finally admitted to my ward, where we successfully substituted her opioids, stabilising both her physical and mental condition.”

After publishing a paper on this particular case, Dr Schellekens and colleagues decided to set up a network to help patients with chronic pain and addiction. “We set-up a research line on this topic with our colleagues from anaesthesiology, the pharmacy, and addiction care,” he explained. “Now we are running a clinical trial on buprenorphine and established a regional pain consortium with general practitioners to prevent an opioid epidemic such as is taking place in the US and Canada.”

Several interventions will be necessary to ensure that such an epidemic does not precipitate in Europe, he explained: “It is crucial to further implement opioid guidelines in order to stimulate adequate or appropriate use of opioids.

“Furthermore, it is important to personalise opioid treatment, based on the risk profile of patients to develop opioid use disorders.”

One example of this may be to prescribe buprenorphine instead of full opioid agonists, he said. “From a scientific point of view, it is very intriguing what the added value is of buprenorphine over full agonists in this group, and especially, why? Is it the partial agonist profile of this compound? Or is it for example its activity on the kappa opioid receptor?”

The latter might be of importance beyond the group patients with chronic pain, he suggested, since the kappa-opioid receptor has shown relevance for other addictive behaviours and even mood disorders. “It might not be a coincidence that mood disorders frequently co-occur in chronic pain patients and are associated with problematic opioid use in this group. As such, this field is of interest for psychiatry as a whole.”

The symposium ‘Chronic pain and risk of addiction’ takes place in Erato from 8:00 to 9:30 this morning.

References
Negative symptoms: new perspectives

A transnosological approach to diagnose and treat negative symptoms across psychiatric disorders will be addressed tomorrow afternoon at the EPA Congress. The session is opened by Armida Mucci, Associate Professor of Psychiatry at the University of Campania Luigi Vanvitelli, Naples, and head of the university’s Psychotherapy unit.

Professor Mucci introduces the implications of cross-diagnostic conceptualisation of negative symptoms. With 25 years of clinical experience in treating patients with schizophrenia and other psychotic disorders, she is also Secretary of EPA Section on Schizophrenia, and a member of the ECNP Network on Schizophrenia.

“I have collaborated on all main clinical and research activities of the Centre for Psychotic Disorders in Naples (led by EPA President Silvana Galderisi), with a focus on cognitive dysfunctions and negative symptoms in schizophrenia,” she said.

Professor Mucci will be addressing domains related to reduced motivation and interest, such as avolition, anhedonia, and asociality (reduced interest and involvement in work, school or pleasurable activities and reduced drive for social bonds). She will also cover the domains relevant to impaired real-life functioning, such as blunted affect and alogia – the reduction of spontaneous speech, especially in social situations.

“These symptoms can be primary or secondary to other factors,” she said. “For example, they may indicate depression and if we treat depression the negative symptoms will improve. “They may indicate psychotic symptoms, where a person does not want to see friends because of ideas of persecution,” she said.

However, such symptoms may simply be side effects of medications, and hence can be ameliorated by reduction of the dose or change in the prescribed drug. They may also be an indicator of environmental factors, such as isolation, said Professor Mucci.

“Secondary negative symptoms are amenable to treatment in most cases, while primary negative symptoms do not respond to the main antipsychotics or to other drugs,” she continued. “For these symptoms, new pharmacological and psychological treatments are being developed and need further testing.”

Professor Mucci’s talk will review and discuss the latest data on the prevalence of negative symptoms in people with schizophrenia or other psychotic disorders, in subjects at risk of psychosis and in those with non-psychotic depression.

“I will show that across diagnostic categories, negative symptoms are associated with poor real-life functioning, particularly with interpersonal problems,” she explained. “In subjects at risk, the presence of negative symptoms of moderate severity, particularly avolition, which persist over the first year of follow-up, predicts conversion to a psychotic disorder. In subjects with depression, negative symptoms are associated with earlier age at onset and poor response to treatment.”

Her research in this area is broad. She has collaborated with the Italian Network for Research on Psychoses, which is led by Professor Mario Maj. “The Italian Network carried out the largest study to date on factors influencing real-life functioning of subjects with schizophrenia,” she explained. “Within that study, I contributed to the introduction of second-generation instruments for the assessment of negative symptoms and to the standardisation of the MATRICS Consensus Cognitive Battery in Italy.”

Indeed, the latest publication of the Italian Network is a complete review of the challenges of the field, said Professor Mucci. “We have looked at which negative symptom domain has an impact on functioning, together with many other factors, using an innovative method – network analysis.”

Such assessment is vital for psychiatrists said Professor Mucci: “Given the impact of negative symptoms on functioning and quality of life, it is important that psychiatrists learn how to assess them,” she said. “Unfortunately, psychiatrists are less skilled in assessing these symptoms with respect to psychotic or depressive symptoms.”

Indeed, the EPA Section on Schizophrenia organised an EPA Itinerant course on assessment of negative symptoms. Professor Mucci held the course in Banja Luka, Bosnia-Herzegovina last year to disseminate information on its importance. “The assessment has clinical implications, as the recognition of secondary negative symptoms will improve the treatment and outcome of affected subjects,” she explained. “In the symposium I will give an update of assessment instruments developed to improve the evaluation of these symptoms.”

There may be a wealth of interventions today, but more needs to be done, she concluded: “The main challenge is to understand better the pathophysiology of primary negative symptoms to develop effective treatments.”

“With this aim in mind, research must adopt the new instruments to assess negative symptoms and researchers must carry out longitudinal studies.

“I would like to see more research funding for this issue, increased awareness in psychiatrists and all stakeholders about these symptoms and the need to improve how we recognise, assess and treat them. I hope the symposium will stimulate the discussion of this issue.”

References
A paradigm shift in neuropsychiatry

New approaches to advancing drug development for the treatment of neuropsychiatric disorders will be outlined in this afternoon’s joint ECNP-EPA symposium. The session will look at the applications of neuroimaging in this area, as well as novel methods for investigating drug effects using human models of emotional processing.

Martien Kas, Professor of Behavioural Neuroscience at the University of Groningen (the Netherlands) will talk about the latest work of a major EU project he coordinates, the Psychiatric Ratings using Intermediate Stratified Markers (PRISM) project.

PRISM will look at integrated translational approaches in psychiatric research, he explained to EPA Congress News: “We have seen a stagnation in the development of new drug targets for psychiatric disorders. This project puts forward a paradigm shift to accelerate drug discovery and treatment. The idea is to cluster patients on the basis of quantitative biology rather than on diagnostic criteria in order to accelerate drug discovery and treatment.”

Traditionally, patients have been classified on the basis of DSM criteria, said Professor Kas. PRISM aims to cluster patients not on the basis of their initial DSM diagnosis, but on quantitative biological measures that are closer to the origin of the disease. Such measures might include EEG, imaging or behavioural assessments.

“We are assessing a whole range of biological measures within specific domains that are seen across disorders rather than in any specific disorder,” he explained. For example, social withdrawal is seen not only in schizophrenia, but also in Alzheimer’s disease and major depression. “We try to zoom in and cluster those patients according to quantitative biological measures within those domains, and see whether we can get more homogeneous clusters of patients based on biology.”

Social withdrawal is a major burden to patients and their caregivers, said Professor Kas. “There is not really a treatment that can take away the burden and the suffering from withdrawal,” he said. “In schizophrenia it may be one of the earliest symptoms, so much closer to the origin of the disease.”

The PRISM group is looking to understand the underlying biology of these domains, he explained. “We are looking at a different level of biology that has not been done before. For example, is there a particular neural circuit that is driving sensory processing deficits in certain patients? Is that particular circuit specific for a group of patients (within schizophrenia, say), is this relevant across different disorders, or is this seen in a wider group of patients irrespective of clinical diagnosis?”

During the symposium, Professor Kas will outline an ongoing exploratory clinical proof-of-concept study that is taking place across Europe, looking at critical patient clusters across Alzheimer’s disease and schizophrenia. At the moment, the group has identified the measures that will be used. Currently, patient recruitment is underway.

And animal models are being developed concurrently: “We will implement phenotyping of biological measures in rodents that are homologous to those assessed in our clinical study,” said Professor Kas. “So by the time we have identified those measures that are critical for this patient clusters, we will be able to continue to study the underlying biology using those homologous phenotypes in animals. That is why this is a novel integrated translational approach with back-translational approach of human findings to rodents.”

He added: “Rather than developing animal models for schizophrenia, we are going more in the direction of animal models for sensory deficits which may be underlying some elements of social withdrawal.”

Many will be watching the outcome of this innovative approach, said Professor Kas. PRISM is funded by the Innovative Medicines Initiative (IMI), which calls for a reclassification of diseases based on their root cause rather than symptoms, and is also based on the recent NIH/NIMH Research Domain Criteria initiative. “People have started to realise that to move the field further we would need novel approaches,” concluded Professor Kas. “I think now both industry as well as academia has started to realise that we need novel approaches and this may be one way to go. People may have thought of this before, but I think we are one of the first to practically implement this new paradigm in a proof of concept study.”

“We are one of the first to practically implement this new paradigm in a proof of concept study.”

Martien Kas

“This project puts forward a paradigm shift to accelerate drug discovery and treatment.”

Martien Kas
ECP Court Debate: Choose Your Career Wisely: Academia and/or Clinical Practice?

Silvana Galderisi joins Robin Murray this afternoon to present the pros and cons of academic and clinical psychiatry practice. Professor Galderisi spoke to EPA Congress News ahead of the session to share her thoughts.

What are the positive aspects of a career in academic psychiatry, such as informing the curriculum, and directing research?
The academic career has several advantages, including the possibility to carry out research activities, interact with colleagues from different contexts and backgrounds, and have easier access to scientific information and research instruments. In addition, teaching activities require a constant update, and offer the opportunity to interact with young students, follow their personal growth, and reconsider your knowledge and approaches with different eyes. In few words, the academic career offers lifelong intellectual stimuli. Besides this, the psychiatrist can provide clinical care, while exploring new models and tools aimed at improving her or his practice.

What characteristics are suited to a career in academic psychiatry?
The academic career is highly competitive, and requires a certain degree of ambition, together with a strong willingness to pursue one’s own goals. The person should be interested in learning and gaining experience abroad, in challenging and stimulating environments, and prepared to ups and downs along the pathway. They should be aware of pros and cons of the academic career, and consider whether they match their personality characteristics.

In your opinion should academic psychiatrists remain in touch with clinical practice?
I think that clinical experience is an important, fundamental pillar of sound research and teaching activities. Combining experience in both fields results in cross-fertilisation and gives the chance to remain on the cutting edge of clinical knowledge. However, this requires time and effort.

When we talk about making a wise choice of career, what role does timing play in terms of moving into academia?
It very much depend on the context. Gaining experience in settings different from academia can be very useful; indeed, there are contexts in which you can gain clinical experience also in the academic setting.

Would you say that there are sufficient numbers of psychiatrists today that are trained in scientific methods?
The number of psychiatrists trained in neuroscience is increasing, but still low. Their presence in neuroscience research is very important, especially to provide an input on the choice of clinical correlates of neurobiological indices, but also on clinically relevant questions the research programs need to address.

The recently-published Women in Academic Psychiatry discusses the experiences of a number of leaders in the field and what led to their success.

What is your advice to women?
Women are often disadvantaged in an academic career. It can be difficult to combine roles as a mother, a professional and an academic. This is why I think that women who succeed in their careers deserve a specific recognition. In addition, women tend to be more cooperative than competitive, and this might be a disadvantage in the academic environment.

For early career psychiatrists looking towards academia, where is the biggest need? Biological psychiatry, or social?
If you mean that biological psychiatry favours the academic career, I would agree only partially. In fact, publishing in neuroscience still is more likely to lead to a high H index than publishing in social psychiatry. However, several colleagues working in social psychiatry do achieve great results and top positions in the academia.

Is there a need to make practising clinical psychiatrists more aware of their role as advocates or lobbyists of policy and research goals in psychiatry? Is this an argument in favour of bringing more clinicians in closer touch with the academic sphere?
I think this is an important role of all psychiatrists, both in clinical and academic settings.

The ECP Court Debate: “Choose Your Career Wisely: Academia and/or Clinical Practice?” takes place in Clio between 17:00 and 18:30 today.

EPA Board and Committees

**EPA Board**

- Silvana Galderisi **Italy** Chair
- Julian Beezhold **UK**
- Geert Dom **Belgium**
- Peter Falkai **Germany**
- Andrea Fiorillo **Italy**
- Wolfgang Gaebel **Germany**
- Paz Garcia-Portilla **Spain**
- Philip Gorwood **France**
- Cécile Hanon **France**
- Nikola Jovanovic **UK**
- Levent Küey **Turkey**
- Tamas Kurimay **Hungary**
- Michael Musalek **Austria**
- Andrea Raballo **Norway**
- Martina Roinic-Kuzman **Croatia**
- Jerzy Samochowicz **Poland**
- Danuta Wasserman **Sweden**

**Early Career Psychiatrists Committee**

- Nikolina Jovanovic **UK** Chair
- Mariana Pinto da Costa **Portugal** Co-Chair
- Katja Koelkebeck **Germany**
- Olga Kazakova **Belarus**
- Dzmitry Krupchanka **Czech Republic**

**Publication Committee**

- Wolfgang Gaebel **Germany** Chair
- Philip Gorwood **France** Co-chair
- Julian Beezhold **UK**
- Peter Falkai **Germany**
- Andrea Fiorillo **Italy**
- Sophia Frangou **USA**
- Silvana Galderisi **Italy**
- Paz Garcia-Portilla **Spain**
- Reinhard Heun **UK**
- Tamas Kurimay **Hungary**
- Michael Musalek **Austria**
- Danuta Wasserman **Sweden**

**EPA 2018 COMMITTEES**

**Scientific Programme Committee (SPC)**

- Silvana Galderisi **Italy** Chair
- Michaela Amering **Austria**
- Julian Beezhold **UK**
- István Bitter **Hungary**
- Philippe Courtet **France**
- Geert Dom **Belgium**
- Karen Erche **UK**
- Wolfgang Gaebel **Germany**
- Paz Garcia-Portilla **Spain**
- Ulrike Schmidt **UK**
- Meryam Schouler-Oçak **Germany**

**Advisory Scientific Programme Committee (ASPC)**

- Dinesh Bhugra **UK**

**Committee on Ethical Issues**

- Danuta Wasserman **Sweden** Chair
- Sue Bailey **UK**
- Cécile Hanon **France**
- Andreas Heinz **Germany**
- Norman Sartorius **Switzerland**
- Rutger Jan van der Gaag **Netherlands**
- Livia Varusova **Slovakia**
- Jan Wise **UK**

**Committee on Education**

- Cécile Hanon **France** Chair, Secretary for Education
- Olivier Andlauer **UK**
- Julian Beezhold **UK**
- Defne Eraslan **Turkey**
- Michael Musalek **Austria**
- Tanja Svirskis **Finland**

**Committee on NPIs Chair**

- Defne Eraslan **Turkey**
- Michael Musalek **Austria**
- Danuta Wasserman **Sweden**

**Local Organising Committee (LOC)**

- Philippe Courtet **Montpellier** Chair
- Michel Benoit **Nice**
- Gilles Bertschy **Strasbourg**
- Renaud David **Nice**
- Sonia Dolfus **Caen**
- Pierre-Alexis Geoffroy **Paris**
- Sébastien Guillaume **Montpellier**
- Emmanuel Haffen **Besançon**
- Yann le Strat **Paris**
- Jorge Lopez Castroman **Nimes**
- Luc Mallet **Paris**
- Emilie Olle **Montpellier**
- Diego Palao **Barcelona** **Spain**
- Emmanuel Poulet **Lyon**
- Nicolas Ramoz **Paris**
- Marie Tournier **Bordeaux**
- Guillaume Vaiva **Lille**
- Inaki Zorrilla **Vitoria** **Spain**

**EPA 2018 FACULTY**

- Michaela Amering **Medical University of Vienna** **Austria**
- Olivier Andlauer **East London NHS Foundation Trust** **UK**
- Goran Arbanas **University Psychiatric Hospital Vrapce** **Croatia**
- Philip Asherson **King's College London** **UK**
- Albert Batalla **Radboudumc** **Netherlands**
- Julian Bezboidh **Norfolk and Suffolk NHS Foundation Trust** **UK**
- Dinesh Bhugra **Institute of Psychiatry** **Psychology & Neuroscience** **UK**
- Istvan Bitter **Semmelweis University** **Budapest** **Hungary**
- Denny Borboom **University of Amsterdam** **Netherlands**
- Vladimir Carli **Karolinska Institutet** **Sweden**
- Christoph Correll **Hofstra Northwell School of Medicine** **USA**
- Philippe Courtet **University of Montpellier** **France**
- Cleo Crunelle **University Hospital Brussels** **Belgium**
- Albert Diefenbacher **Charité – University Medicine Berlin** **Germany**
- Sonia Dollfus **University Normandie Caen** **France**

**EPA Congress News** 5 March 2018 Monday
Emmanuel Haffen University Hospital of Besançon France
Peter Handest Mental Health Center North Zealand Denmark
Cecile Hanon Resource Regional Center of Old Age Psychiatry France
Josep Maria Haro Parc Sanitari Sant Joan de Deu Spain
Andreas Meyer Heinz Charité - Universitätsmedizin Germany
Claire Henderson King’s College London UK
Marc Herrmans HET PARK Belgium
Sabine Herpertz EPA Germany
Helen Herrman The University of Melbourne Australia
Reinhard Heun DHCFT UK
Louise Howard King’s College London UK
Nikolina Jovanovic Queen Mary University of London UK
Stefan Kaiser Geneva University Hospitals Switzerland
Martien Kas University of Groningen the Netherlands
Marianne Kastrup Freelance Denmark
Olga Kazakova Psychiatric Clinic of Minsk City Belarus
Oussama Kebir INSERM U894 France
Katja Koelkebeck University of Antwerp Belgium
Dzmitry Krupchanka National Institute of Mental Health Czech Republic
Levent Küey Istanbul Bilgi University Turkey
Tamas Kurimay Semmelweis University Hungary
Stefan Leucht Technischen Universität Muecheen Germany
Greg Lydall HSC Guernsey UK
Mario Maj Department of Psychiatry University of Naples SUN Italy
Mia Männikkö EUPAM Finland
Frieleh Matthias Vrije Universiteit Brussel Belgium
Peter McGovern World Health Organisation Switzerland
Andrew McIntosh University of Edinburgh UK
Andreas Meyer-Lindenberg Medical Faculty Mannheim Heidelberg Germany
Ellenor Mittendorfer-Rutz Karolinska Institutet Sweden
Stirling Moorey South London and Maudsley NHS Trust UK
Armida Mucci University of Campania Luigi Vanvitelli Italy
Davor Mucic Little Prince Psychiatric Center Denmark
Susannah Murphy University of Oxford UK
Robin Murray King’s College London UK
Chris Nas Trimbos Institute Netherlands
Merete Nordentoft Mental Health Center Copenhagen University of Copenhagen Denmark
Emilie Ollie CHU Montpellier France

Mariana Pinto de Costa Hospital de Magalhães Lemos University of Porto Portugal
Bernd Puschner Ulm University Germany
Andrea Raballo Norwegian University of Science and Technology (NTNU) Italy
Greg Radu Memorial University Canada
Josep Antoni Ramo Spain
Nicolas Ramoz INSERM France
Geoffrey Reed Mexico
Martina Rojnic-Kuzman Zagreb School of Medicine and Zagreb University Hospital Centre Croatia
Howard Ryland South West London and St. George’s Mental Health NHS Trust UK
Jerzy Samochowiec EPA Poland
Marco Sarchiapone University of Molise Italy
Norman Sartorius Association for the Improvement of Mental Health Programmes Switzerland
Ulrike Schmidt King’s College London UK
Meryam Schouler-Ocak Charité - Universitätsmedizin Berlin Germany
Ivana Silva European Medicines Agency UK
Esther Sobanski Germany
Ekin Sonmez Marmara University Turkey
Nicola Specchio Bambino Gesu Children’s Hospital Italy
Gabriela Stoppe MentalAge Basel Switzerland
Michela Tinelli LSE UK
Timothea Toulopoulou Bilkent University Turkey
Marie Tournier University of Bordeaux France
Janet Treasure KCL UK
Sam Tyano Tel Aviv university Israel
Lucia Valmaggia King’s College London UK
Wim van den Brink Academic Medical Center University of Amsterdam Netherlands
Neeltje Van Haren University Medical Centre Utrecht Netherlands
Joris Vandenbergh University Hospitals Leuven; University Psychiatric Hospital UPC KULeuven; University of Leuven Belgium
Eduard Vieta Hospital Clinic Spain
Sabine Vollstädt-Klein Central Institute of Mental Health Germany
Danuta Wasserman NASP Karolinska Institutet Sweden
Jan Wise CNWL NHS Trust UK
Til Wykes King’s College London UK
Sonam Zami University of Plymouth UK
Laure Zeltner EPA France

MediFore are the proud publishers of EPA CONGRESS NEWS

MediFore is a full-service medical communications and publishing company, working closely with local and international medical societies and associations, and industry, to develop conference publications, including newsletters and newspapers, as well as reports and medical summaries, medical writing and scientific publications

enquiries@medifore.co.uk
+44 (0) 20 8761 2790
8th EPA Summer School

ABCs of Psychotherapy

"I was able to improve my communication skills in a very positive setting and learn useful basics of different types of psychotherapy which I could implement in my daily practice."

- 2017 Scholar

Apply now on the EPA website & join us at the next Summer School!

6 - 9 September 2018 Strasbourg, France

European Psychiatric Association

www.europsy.net #EPASummerSchool